Martinsried - San Diego, October 18, 2005: In the final round of the European Biotechnica Awards 2005, the German-American biotech company MediGene AG (Prime Standard, TecDax: MDG) was honored with the first price. During yesterday's ceremony, Dr. Peter Heinrich, Chief Executive Offier of MediGene AG, accepted the award in the presence of the Federal Minister for Economics, Wolfgang Clement.
The Biotechnica Award, endowed with 40,000 Euros, is awarded by the Deutsche Messe AG to European biotech and life science companies for the third time. The assessment criteria are marketability and relevance of products and services, as well as marketing concept and innovative achievement in research and development.
The Biotechnica is the largest European biotech trade show with approximately 900 exhibiting companies and an anticipated 10,000 visitors who keep themselves informed about the latest developments in biotechnology.
"We are very happy to have made it to the top, with our second participation. The jury rewarded how consistently we embark on our strategy of becoming a fully integrated biopharmaceuticals company", Dr. Peter Heinrich comments.
- Ende -
MediGene AG is a publicly quoted (Frankfurt: Prime Standard), German-American biotechnology company located in Martinsried, Germany and San Diego, USA. MediGene is the first German biotech company with a drug on the market. The NDA for a second drug has recently been submitted. In addition, MediGene has several oncological drug candidates undergoing clinical development, and possesses innovative platform technologies for drug development. MediGene's core competence lies in research into and development of novel approaches for the treatment of various cancer and tumor diseases.
Contact MediGene AG
Fax:++49 - 89 - 85 65- 2920
Dr. Georg Dönges, Public Relations, Tel.: ++49 - 89 - 85 65 - 3317
Dr. Michael Nettersheim, Investor Relations, Tel.: ++49 - 89 - 85 65 - 2946